microRNA Biomarkers as Potential Diagnostic Markers for Cancer - Genomic Biomarkers for Pharmaceutical Development - page 115

[11] Jansen H, Reesink H, Zeuzem S, Lawitz E, Rodriguez-Torres M, Chen A. AASLD 2011.
[12] Reesink H, Janssen H, Zeuzem S. Forty seventh International Liver Congress (European Association for the
Study of the Liver 2012) Barcelona. April 18-22, 2012.
[13] Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012;3:120.
[14] Szafranska-Schwarzbach AE, Adai AT, Lee LS, Conwell DL, Andruss BF. Development of a miRNA-based
diagnostic assay for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn 2011;11:249-57.
[15] Dobbin KK, Simon RM. Sample size planning for developing classiiers using high-dimensional DNA micro-
array data. Biostatistics 2007;8:101-17.
[16] Dobbin KK, Zhao Y, Simon RM. How large a training set is needed to develop a classiier for microarray
data? Clin Cancer Res 2008;14:108-14.
[17] Tibshirani R. A simple method for assessing sample sizes in microarray experiments. BMC Bioinformatics
2006;7:106.
[18] Lee ML, Whitmore GA. Power and sample size for DNA microarray studies. Stat Med 2002;21:3543-70.
[19] Page GP, Edwards JW, Gadbury GL, Yelisetti P, Wang J, Trivedi P, et al. The PowerAtlas: a power and sample
size atlas for microarray experimental design and research. BMC Bioinformatics 2006;7:84.
[20] Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of
sensitivity to preoperative chemotherapy with paclitaxel and luorouracil, doxorubicin, and cyclophospha-
mide in breast cancer. J Clin Oncol 2006;24:4236-44.
[21] Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, et al. Systematic review: gene
expression proiling assays in early-stage breast cancer. Ann Intern Med 2008;148:358-69.
[22] Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based sur-
vival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
[23] Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression proiles to predict distant
metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
[24] Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control
(MAQC)-II study of common practices for the development and validation of microarray-based predictive
models. Nat Biotechnol 2010;28:827-38.
[25] Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classiication of can-
cer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
[26] van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression proiling predicts
clinical outcome of breast cancer. Nature 2002;415:530-6.
[27] Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression proiles predict
survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
[28] Fielden MR, Adai A, Dunn II RT, Olaharski A, Searfoss G, Sina J, Predictive Safety Testing Consortium,
Carcinogenicity Working Group. Development and evaluation of a genomic signature for the prediction and
mechanistic assessment of nongenotoxic hepatocarcinogens in the rat. Toxicol Sci 2011;124:54-74.
[29] Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on
statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-57.
[30] Simon R. Roadmap for developing and validating therapeutically relevant genomic classiiers. J Clin Oncol
2005;23:7332-41.
[31] Simon R. Interpretation of genomic data: questions and answers. Semin Hematol 2008;45:196-204.
[32] Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in
microarray experiments. Bioinformatics 2005;21:2067-75.
[33] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics 2010;26:139-40.
[34] J. Andre Knottnerus (Ed). The Evidence Base of Clinical Diagnosis. London: BMJ Publishing Group; 2002.
[35] Subramanian J, Simon R. What should physicians look for in evaluating prognostic gene-expression signa-
tures? Nat Rev Clin Oncol 2010;7:327-34.
[36] Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies: time for action. Clin
Chem 2008;54:1101-3.
[37] Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the qual-
ity assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol
2003;3:25.